These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

975 related articles for article (PubMed ID: 28460546)

  • 1. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
    Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
    Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
    Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
    Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive minimization with mTOR inhibitors and belatacept.
    Diekmann F
    Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients.
    Divard G; Aubert O; Debiais-Deschamp C; Raynaud M; Goutaudier V; Sablik M; Sayeg C; Legendre C; Obert J; Anglicheau D; Lefaucheur C; Loupy A
    Clin J Am Soc Nephrol; 2024 May; 19(5):628-637. PubMed ID: 38265815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation.
    Kamar N; Del Bello A; Belliere J; Rostaing L
    Transpl Int; 2015 Aug; 28(8):928-37. PubMed ID: 25557802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belatacept based immunosuppression: What and when to combine?
    Schilsky J; Dvorai RH; Yang C; Suo L; Saracino G; Shahbazov R
    Transpl Immunol; 2024 Aug; 85():102050. PubMed ID: 38810889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological risks of minimization strategies.
    Snanoudj R; Tinel C; Legendre C
    Transpl Int; 2015 Aug; 28(8):901-10. PubMed ID: 25809144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.
    Choi M; Bachmann F; Wu K; Lachmann N; Schmidt D; Brakemeier S; Duerr M; Kahl A; Eckardt KU; Budde K; Nickel P
    BMC Nephrol; 2020 Aug; 21(1):354. PubMed ID: 32819287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients.
    Sethi S; Najjar R; Peng A; Choi J; Lim K; Vo A; Jordan SC; Huang E
    Transplantation; 2020 Jul; 104(7):1500-1507. PubMed ID: 31568398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
    Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
    J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
    Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
    PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcineurin-inhibitor-sparing immunosuppressive protocols.
    Bestard O; Cruzado JM; Grinyó JM
    Transplant Proc; 2005 Nov; 37(9):3729-32. PubMed ID: 16386520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
    Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed.
    Webber AB; Vincenti F
    Transplantation; 2016 Apr; 100(4):836-43. PubMed ID: 27003097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A safety evaluation of belatacept for the treatment of kidney transplant.
    Garcia VD; Meinerz G; Keitel E
    Expert Opin Drug Saf; 2016 Aug; 15(8):1125-32. PubMed ID: 27309154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
    Budde K; Prashar R; Haller H; Rial MC; Kamar N; Agarwal A; de Fijter JW; Rostaing L; Berger SP; Djamali A; Leca N; Allamassey L; Gao S; Polinsky M; Vincenti F
    J Am Soc Nephrol; 2021 Dec; 32(12):3252-3264. PubMed ID: 34706967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.
    Camilleri B; Bridson JM; Halawa A
    Exp Clin Transplant; 2016 Oct; 14(5):471-483. PubMed ID: 27213490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcineurin inhibitor-free protocols: risks and benefits.
    Barbari AG; Stephan AG; Masri MA
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):1-23. PubMed ID: 17237886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are calcineurin inhibitors-free regimens ready for prime time?
    Vincenti F
    Kidney Int; 2012 Nov; 82(10):1054-60. PubMed ID: 22622502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.